Lindsey Shapiro, PhD,  science writer—

A European Medicines Agency (EMA) committee has recommended the approval of Argenx’s under-the-skin, or subcutaneous, formulation of efgartigimod as an add-on to standard therapy for adults with generalized myasthenia gravis (gMG) who have antibodies against acetylcholine receptors (AChRs). Argenx’s into-the-vein (intravenous) formulation of efgartigimod, sold as Vyvgart,…

A cell-based assay for detecting myasthenia gravis (MG)-causing antibodies in the blood results in greater diagnostic accuracy than two other antibody tests, according to data from a study in China. The cell-based assay (CBA) was superior to enzyme-linked immunoabsorbent assay (ELISA) and radioactivity radioimmunoprecipitation assay (RIPA) at detecting antibodies…

Most people with childhood-onset myasthenia gravis (CMG) experience milder clinical symptoms and a better prognosis than those with adult forms of the disease, according to a recent study in China. For most CMG patients, their disease could be safely controlled with prednisone and other immunosuppressive agents. Researchers also found…

The targeted generalized myasthenia gravis (gMG) treatment Rystiggo (rozanolixizumab-noli) is now commercially available by prescription in the U.S. for eligible adults with gMG, including individuals with antibodies against either the acetylcholine receptor (AChR) or muscle-specific kinase (MuSK), according to its developer. In late June, the therapy from…

On June 27, Rystiggo became the first generalized myasthenia gravis (gMG) treatment to be approved by the U.S. Food and Drug Administration (FDA) for adults with antibodies against either the acetylcholine receptor (AChR) or muscle-specific kinase (MuSK) proteins. While other treatments have been cleared for patients with anti-AChR…

An under-the-skin formulation of efgartigimod is now being considered for approval in China for treating adults with generalized myasthenia gravis (gMG), according to Zai Lab, which will market the therapy if approved. Chinese authorities have agreed to review a biologics license application (BLA) seeking the approval of this…

Descartes-08, an investigational RNA-based CAR T-cell therapy (rCAR-T), safely eased disease symptoms for up to nine months after treatment among 14 adults with generalized myasthenia gravis (gMG) taking part in a Phase 1b/2a clinical trial. The open-label MG-001 trial (NCT04146051), now a recruiting Phase 2b study, is the…

The U.S. Food and Drug Administration (FDA) has approved rozanolixizumab, under the brand name Rystiggo, to treat adults with generalized myasthenia gravis (gMG) who have antibodies against the acetylcholine receptor (AChR) or muscle-specific tyrosine kinase (MuSK) proteins. Rystiggo is now the only FDA-approved therapy for patients with anti-AChR…

A subset of immune cells called natural killer (NK) cells are elevated in the blood of myasthenia gravis (MG) patients with active disease symptoms, where they may promote an autoimmune response, according to a recent study. These cells, which house the CXCR5 protein on their surface, was linked to…

More generalized myasthenia gravis (gMG) patients who received Ultomiris (ravulizumab) in the Phase 3 CHAMPION MG trial achieved a favorable clinical response to treatment relative to those taking a placebo, according to new trial analyses. The proportion of patients achieving that milestone, according to the Myasthenia Gravis Foundation…